ArticleThe New England journal of medicine2014
Bevacizumab in glioblastoma--still much to learn.
Article in The New England journal of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials.iScience · 2025Review
- New Anti-Angiogenic Therapy for Glioblastoma With the Anti-Depressant Sertraline.Cancer medicine · 2024Article
- Expression of TMEM59L associated with radiosensitive in glioblastoma.Journal of radiation research · 2023Article
- Graphene Oxide Nanoscale Platform Enhances the Anti-Cancer Properties of Bortezomib in Glioblastoma Models.Advanced healthcare materials · 2023Article
- Isolinderalactone inhibits glioblastoma cell supernatant-induced angiogenesis.Oncology letters · 2022Article
- Hypoxia-induced GLT8D1 promotes glioma stem cell maintenance by inhibiting CD133 degradation through N-linked glycosylation.Cell death and differentiation · 2022Article
- Review
- Review
- EGFL7 enhances surface expression of integrin αEMBO molecular medicine · 2018Article
- Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.Clinical immunology (Orlando, Fla.) · 2018Review
- Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials.Cancer management and research · 2018Article
- The Microenvironmental Landscape of Brain Tumors.Cancer cell · 2017Review
- Normalizing Tumoral Vessels to Treat Cancer: An Out-of-the-Box Strategy Involving TIE2 Pathway.Translational cancer research · 2017Article
- Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism.Radiation research · 2017Article
- Predictors of Venous Thromboembolism in Patients with Glioblastoma.Pathology oncology research : POR · 2016Article
- Current status and future directions of anti-angiogenic therapy for gliomas.Neuro-oncology · 2016Review
- Molecular heterogeneity of glioblastomas: does location matter?Oncotarget · 2016Article
- The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.Advances in pharmacology (San Diego, Calif.) · 2016Review
- Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Article
- Deleterious c-Cbl Exon Skipping Contributes to Human Glioma.Neoplasia (New York, N.Y.) · 2015Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
24552324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.